NCT02344862 - Study of FYU-981 in Hyperuricemia With or Without Gout | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

September 30, 2014

Conditions

Hyperuricemia

Interventions

DRUG

FYU-981 High dose, (Oral daily dosing for 8 weeks)

Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.

DRUG

FYU-981 Middle dose, (Oral daily dosing for 8 weeks)

Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.

DRUG

FYU-981 Low dose, (Oral daily dosing for 8 weeks)

Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.

DRUG

Placebo, (Oral daily dosing for 8 weeks)

Subjects randomized to the placebo arm receive placebo.

Trial Locations (1)

Japan, Tokyo